Glucocorticoid withdrawal-an overview on when and how to diagnose adrenal insufficiency in clinical practice
Open accessThe DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index; 21 of the 88 sources its claims cite were checked for support.
Abstract
Glucocorticoids (GCs) are widely used due to their anti-inflammatory and immunosuppressive effects. As many as 1–3% of the population are currently on GC treatment. Prolonged therapy with GCs is associated with an increased risk of GC-induced adrenal insufficiency (AI). AI is a rare and often underdiagnosed clinical condition characterized by deficient GC production by the adrenal cortex. AI can be life-threatening; therefore, it is essential to know how to diagnose and treat this disorder. Not only oral but also inhalation, topical, nasal, intra-articular and intravenous administration of GCs may lead to adrenal suppression. Moreover, recent studies have proven that short-term (<4 weeks), as well as low-dose (<5 mg prednisone equivalent per day) GC treatment can also suppress the hypothalamic–pituitary–adrenal axis. Chronic therapy with GCs is the most common cause of AI. GC-induced AI remains challenging for clinicians in everyday patient care. Properly conducted GC withdrawal is crucial in preventing GC-induced AI; however, adrenal suppression may occur despite following recommended GC tapering regimens. A suspicion of GC-induced AI requires careful diagnostic workup and prompt introduction of a GC replacement treatment. The present review provides a summary of current knowledge on the management of GC-induced AI, including diagnostic methods, treatment schedules, and GC withdrawal regimens in adults.
Overview
CoChat Summary
TL;DR
Glucocorticoid-induced adrenal insufficiency (AI) is an underdiagnosed, potentially life-threatening complication of glucocorticoid therapy that can occur even with short-term or low-dose treatment and non-oral routes. This narrative review summarizes diagnostic approaches, glucocorticoid withdrawal regimens, HPA-axis recovery, and replacement treatment in adults.
Key findings
- As many as 1–3% of the population are currently on glucocorticoid treatment, and AI after glucocorticoid withdrawal has been estimated at 48.7% for oral administration, 7.8% for inhalation, 4.7% for topical, and 4.2% for nasal administration.
- Morning serum cortisol below 3 μg/dL rules in AI, while levels above 18 μg/dL practically rule out AI; dynamic testing is suggested when morning cortisol is between 3 and 15 μg/dL.
- Normal age- and sex-adjusted DHEA-S predicts proper HPA-axis function with sensitivity 87.1%, specificity 86.7%, and positive predictive value 93.1%, though DHEA-S alone is a worse parameter than morning serum cortisol for GC-induced AI.
- Recommended replacement for GC-induced AI is 15–20 mg/day of short-acting hydrocortisone; GC-induced AI may last up to 2–4 years after withdrawal, and recovery is unlikely after 4 years from diagnosis.
Methods
- Narrative review of current knowledge on GC-induced AI in adults, including diagnostic methods, treatment schedules, and glucocorticoid withdrawal regimens.
- No primary study design, sample, or statistical analysis is reported; the paper synthesizes prior literature, guidelines, and cited studies.
- The review discusses baseline and dynamic adrenal testing, including SST, ITT, metyrapone, CRH, and glucagon stimulation tests, as well as MRI consideration and peri-operative stress dosing.
Limitations
- The paper states that predictors of GC-induced AI have not been well identified, the right choice of stimulation test remains debated, and specific guidelines on the duration and regimen of glucocorticoid withdrawal are lacking.
- The paper states that the utility of metyrapone, glucagon, and CRH stimulation tests in diagnosing GC-induced AI has not been sufficiently investigated, and HPA-axis suppression with IV glucocorticoids requires further investigation.
- Evident from the text: this is a narrative review without a described systematic search strategy, quality appraisal, or meta-analysis, so recommendations depend on cited guidelines and selected literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
15 Valid · 0 Not valid · 37 Not checked · 2 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“It is certain that the administration of oral GCs, long-term and in high doses, may cause GC-induced AI [7,8,9,10].”
§ Glucocorticoid Withdrawal—An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice > 1. Introduction
What the sources say
- Not checked yetcites [7] Broersen L.H.A. Pereira A.M. Jørgensen J.O.L. Dekkers O.M. Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis J. Clin. Endocrinol. Metab. 2015 100 2171 2180 10.1210/jc.2015-1218 25844620 source
- Supportedcites [8] Joseph R.M. Hunter A.L. Ray D.W. Dixon W.G. Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review Semin. Arthritis Rheum. 2016 46 133 141 10.1016/j.semarthrit.2016.03.001 27105755 PMC4987145 source
The Introduction states that glucocorticoids can suppress the HPA axis and leave patients with adrenal insufficiency after treatment stops; it also discusses long-term oral glucocorticoid use. The Results report adrenal insufficiency among patients with high cumulative exposure, supporting the claim that long-term, high-dose oral use may cause it. The review also finds risk at lower doses and shorter durations, but the claim does not exclude those exposures. (LLM, conf=0.90)
- Not checked yetcites [9] Sacre K. Dehoux M. Chauveheid M.P. Chauchard M. Lidove O. Roussel R. Papo T. Pituitary-Adrenal Function After Prolonged Glucocorticoid Therapy for Systemic Inflammatory Disorders: An Observational Study J. Clin. Endocrinol. Metab. 2013 98 3199 3205 10.1210/jc.2013-1394 23760625 source
- Supportedcites [10] Karangizi A.H.K. Al-Shaghana M. Logan S. Criseno S. Webster R. Boelaert K. Hewins P. Harper L. Glucocorticoid induced adrenal insufficiency is common in steroid treated glomerular diseases—Proposed strategy for screening and management BMC Nephrol. 2019 20 154 10.1186/s12882-019-1354-6 31060510 PMC6503364 source
The Background states that chronic glucocorticoid inhibition of the HPA axis can cause adrenal insufficiency after withdrawal and that adrenal insufficiency is common after oral corticosteroid use. It also reports a relationship with dose and duration, while cautioning that insufficiency can occur after shorter courses and lower cumulative doses. (LLM, conf=0.90)
boostedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Not only oral but also inhalation, topical, nasal, intra-articular and intravenous administration of GCs may lead to adrenal suppression.”
- Also stated in: § 1. Introduction · boosted
“Several studies have also proven that inhalation, topical, nasal, intra-articular, as well as intravenous (IV) administration of GCs may cause the suppression of the HPA axis [8,17,18,19,20,21,22,23].”
§ Glucocorticoid Withdrawal—An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice > Abstract
What the sources say
- Partly supportedcites [8] Joseph R.M. Hunter A.L. Ray D.W. Dixon W.G. Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review Semin. Arthritis Rheum. 2016 46 133 141 10.1016/j.semarthrit.2016.03.001 27105755 PMC4987145 sourceExperimental — accuracy not yet measured
The Introduction says glucocorticoids can suppress the HPA axis, and Methods > Eligibility criteria includes oral and intravenous administration among the systemic routes studied. But the same section excludes local glucocorticoid use—including topical, inhaled and intra-articular use—and Methods > Search strategy excludes papers studying only local glucocorticoids. This review therefore does not establish the claim for all the listed routes. (LLM, conf=0.90)
- Not checked yetcites [17] Habib G. Jabbour A. Artul S. Hakim G. Intra-articular methylprednisolone acetate injection at the knee joint and the hypothalamic–pituitary–adrenal axis: A randomized controlled study Clin. Rheumatol. 2014 33 99 103 10.1007/s10067-013-2374-4 23982564 source
- Partly supportedcites [18] Gazis A.G. Homer J.J. Henson D.B. Page S.R. Jones N.S. The effect of six weeks topical nasal betamethasone drops on the hypothalamo-pituitary-adrenal axis and bone turnover in patients with nasal polyposis Clin. Otolaryngol. Allied Sci. 1999 24 495 498 10.1046/j.1365-2273.1999.00299.x 10606995 sourceExperimental — accuracy not yet measured
The Discussion reports HPA-axis suppression after topical nasal betamethasone drops, and the introductory passage says inhaled corticosteroids can also suppress the HPA axis. Our copy does not establish the claim for oral, non-nasal topical, intra-articular, or intravenous glucocorticoid administration; its intravenous administration concerns ACTH testing, not glucocorticoid treatment. Page numbers are not available in the indexed passages. (LLM, conf=0.88)
- Not checked yetcites [19] Lipworth B.J. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis Arch. Intern. Med. 1999 159 941 955 10.1001/archinte.159.9.941 10326936 source
- Not checked yetcites [20] Fisher D.A. Adverse effects of topical corticosteroid use West. J. Med. 1995 162 123 7794369 PMC1022645
- Not checked yetcites [21] Walsh P. Aeling J.L. Huff L. Weston W.L. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids J. Am. Acad. Dermatol. 1993 29 501 503 10.1016/S0190-9622(08)82011-7 8349876 source
- Not checked yetcites [22] White M. Crisalida T. Li H. Economides A. Kaliner M. Effects of long-term inhaled corticosteroids on adrenal function in patients with asthma Ann. Allergy Asthma Immunol. 2006 96 437 444 10.1016/S1081-1206(10)60911-8 16597078 source
- Partly supportedcites [23] Woods C.P. Argese N. Chapman M. Boot C. Webster R. Dabhi V. Grossman A.B. Toogood A.A. Arlt W. Stewart P.M. Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol Eur. J. Endocrinol. 2015 173 633 642 10.1530/EJE-15-0608 26294794 PMC4588051 sourceExperimental — accuracy not yet measured
The Results sections report adrenal suppression among patients taking oral, inhaled, and topical glucocorticoids; the Abstract Results also includes intranasal treatment in the studied cohort. The cited paper does not address intra-articular or intravenous administration as causes of adrenal suppression, so it does not support the full list of routes. (LLM, conf=0.88)
boostedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 1. Introduction · boosted
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recent studies have shown that the treatment with an IV methylprednisolone administered every week protocol (cumulative dose of 4.5 g) does not cause GC-induced AI [24,25,26,27].”
§ Glucocorticoid Withdrawal—An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice > 1. Introduction
What the sources say
- Supportedcites [24] Ambroziak U. Bluszcz G. Bednarczuk T. Miśkiewicz P. The influence of Graves’ orbitopathy treatment with intravenous glucocorticoids on adrenal function Endokrynol. Pol. 2017 68 430 433 10.5603/EP.a2017.0036 28604944 source
The Treatment schedule describes weekly IV methylprednisolone pulses totaling 4.5 g. The Results report that all 20 patients had sufficient adrenal function at cessation of IV treatment, and the Discussion concludes that IV treatment was not associated with adrenal insufficiency in this study. One patient developed decreased adrenal reserve only after subsequent oral prednisone therapy. Page numbers are not provided in our copy. (LLM, conf=0.91)
- Supportedcites [25] Pelewicz K. Szewczyk S. Miśkiewicz P. Treatment with Intravenous Methylprednisolone in Patients with Graves’ Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate J. Clin. Med. 2020 9 3233 10.3390/jcm9103233 PMC7601692 33050327 source
The Conclusions state that weekly IV methylprednisolone totaling 4.5 g did not lead to secondary adrenal insufficiency. The Discussion reports that none of the patients developed it at the end of IV treatment; the paper distinguishes this from one case after subsequent oral prednisone. (LLM, conf=0.92)
- Partly supportedcites [26] Jespersen S. Nygaard B. Kristensen L.Ø. Methylprednisolone Pulse Treatment of Graves’ Ophthalmopathy Is Not Associated with Secondary Adrenocortical Insufficiency Eur. Thyroid J. 2015 4 222 225 10.1159/000440834 26835424 PMC4716422 sourceExperimental — accuracy not yet measured
The Materials and Methods describe weekly intravenous methylprednisolone totaling 4.5 g, and the Discussion reports no adrenocortical insufficiency among 12 patients. But the Discussion says the study was limited by its size and that HPA-axis function *seems* essentially unchanged; it does not establish the categorical claim that the protocol cannot cause insufficiency. (LLM, conf=0.87)
- Not checked yetcites [27] Giotaki Z. Fountas A. Tsirouki T. Bargiota A. Tigas S. Tsatsoulis A. Adrenal reserve following treatment of graves’ orbitopathy with intravenous glucocorticoids Thyroid 2015 25 462 463 10.1089/thy.2014.0533 25602127 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The probability of the suppression of the HPA axis cannot be estimated given the potency, dose, or duration of GC treatment as it does not only depend on these factors but also on different GC metabolism between patients [8,14,15].”
§ Glucocorticoid Withdrawal—An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice > 1. Introduction
What the sources say
- Partly supportedcites [8] Joseph R.M. Hunter A.L. Ray D.W. Dixon W.G. Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review Semin. Arthritis Rheum. 2016 46 133 141 10.1016/j.semarthrit.2016.03.001 27105755 PMC4987145 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked yetcites [14] Hill M.R. Szefler S.J. Ball B.D. Bartoszek M. Brenner A.M. Monitoring glucocorticoid therapy: A pharmacokinetic approach Clin. Pharmacol. Ther. 1990 48 390 398 10.1038/clpt.1990.167 2225699 source
- Not checked yetcites [15] Tornatore K.M. Logue G. Venuto R.C. Davis P.J. Pharmacokinetics of Methylprednisolone in Elderly and Young Healthy Males J. Am. Geriatr. Soc. 1994 42 1118 1122 10.1111/j.1532-5415.1994.tb06219.x 7930339 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“It was, however, proven that this therapy affects adrenal function, causing more severe impairment of DHEA-S secretion than that of cortisol [25].”
§ Glucocorticoid Withdrawal—An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice > 1. Introduction
What the sources say
- Supportedcites [25] Pelewicz K. Szewczyk S. Miśkiewicz P. Treatment with Intravenous Methylprednisolone in Patients with Graves’ Orbitopathy Significantly Affects Adrenal Function: Assessment of Serum, Salivary Cortisol and Serum Dehydroepiandrosterone Sulfate J. Clin. Med. 2020 9 3233 10.3390/jcm9103233 PMC7601692 33050327 source
The Abstract (p. 1) states verbatim that 'Treatment with IVMP in a cumulative dose of 4.5 g affects adrenal function, causing more severe impairment of DHEA-S secretion than that of cortisol', and the Discussion (p. ~8) repeats the conclusion, grounding it in the significant fall in serum DHEA-S before the 12th pulse (p = 0.015) with no significant decrease in serum or salivary cortisol (p = 0.165 and p = 0.638; Results, p. ~4). The only qualifier the citing sentence drops is the cumulative dose (4.5 g) in patients with Graves' orbitopathy, which the surrounding text of the citing paper already establishes as the therapy under discussion. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
29 more claims · 8 with their cited sources checked
Create a free account to see all 54 claims and to verify the 67 references still open.
- It may state two separate claims as one. 7
- Probably not a substantial claim. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Persistent impairment of cortisol secretion beyond four years suggests that recovery of adrenal function is very unlikely and long-term glucocorticoid replacement should be continued (99, 124).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [124]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Prior studies have shown that adrenal insufficiency may last even up to 2-4 years after glucocorticoid cessation, owing to slow recovery of adrenal cortisol production (40, 47, 122-124).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [124]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Glucocorticoid Withdrawal—An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice > 4. Recovery of the HPA Axis
“Repeating SST annually is suggested if the patient shows a response to SST with delta cortisol <3.6 μg/dL (where delta cortisol means a cortisol value at 30-min minus basal cortisol value) or 30-min cortisol <12.7 μg/dL.”
§ Glucocorticoid Withdrawal—An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice > 4. Recovery of the HPA Axis
“SST should be performed every 6 months if delta cortisol is >3.6 μg/dL or 30-min cortisol >12.7 μg/dL.”
Citations
Cites
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769 · cited 1×
“While SDT is considered the “gold standard” for establishing primary AI diagnosis [50], some researchers favor LDT in making the diagnosis of secondary AI [51].”
BackgroundHormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945 · cited 2×
“The Endocrine Society suggests performing dynamic testing, which is essential for making the diagnosis of AI, when the morning cortisol level is between 3 and 15 μg/dL [33].”
BackgroundSystemic Adverse Effects of Inhaled Corticosteroid Therapy: A Systematic Review and Meta-analysis
Lipworth, B. J. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.9.941 · Cited by 918
Charmandari, E., Nicolaides, N. C., & Chrousos, G. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61684-0 · Cited by 644
Use of oral corticosteroids in the United Kingdom
van Staa, T. P. (2000) · QJM · doi:10.1093/qjmed/93.2.105 · Cited by 529 · cited 1×
“As many as 1–3% of the population are currently on GC treatment [3,4].”
BackgroundDaily cortisol production rate in man determined by stable isotope dilution/mass spectrometry
ESTEBAN, N. V., LOUGHLIN, T., YERGEY, A. L., ZAWADZKI, J. K., BOOTH, J. D., WINTERER, J. C., & LORIAUX, D. L. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-39 · Cited by 481 · cited 1×
“Current estimates of endogenous daily cortisol production averages 6–11 mg/m2/day [64,65], an amount equivalent to 15–20 mg/day of exogenous hydrocortisone.”
BackgroundDiagnosis and management of adrenal insufficiency
Bancos, I., Hahner, S., Tomlinson, J., & Arlt, W. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70142-1 · Cited by 467 · cited 4×
“Hydrocortisone should be discontinued for 24 h before dynamic tests [44,45].”
BackgroundInfluentialAdrenal insufficiency in corticosteroids use: systematic review and meta-analysis
Broersen, L. H. A., Pereira, A. M., Jørgensen, J. O. L., & Dekkers, O. M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1218 · Cited by 456
Measuring cortisol in serum, urine and saliva—Are our assays good enough?
El-Farhan, N., Rees, D. A., & Evans, C. (2017) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563216687335 · Cited by 395 · cited 2×
“Moreover, the specificity of the assays used for salivary cortisol measurement (first and second-generation electrochemiluminescence assays and liquid chromatography-mass spectrometry) was proven to be low [38].”
BackgroundHahner, S., Spinnler, C., Fassnacht, M., Burger-Stritt, S., Lang, K., Milovanovic, D., Beuschlein, F., Willenberg, H. S., Quinkler, M., & Allolio, B. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3191 · Cited by 394 · cited 1×
“Abrupt reduction or cessation of exogenous GCs may precipitate symptoms of AI or lead to adrenal crisis [13].”
Background
Research works printed but not linked: 1
- Carroll T.B. Aron D.C. Findling J.W. Tyrrell J.B. Glucocorticoids and Adrenal Androgens Greenspan’s Basic & Clinical Endocrinology 10th ed. Gardner D.G. Shoback D. McGraw-Hill Education New York, NY, USA 2017 Available online: https://accessmedicine.mhmedical.com/content.aspx?bookid=2178§ionid=166249274 (accessed on 19 April 2021)
Cited by
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae250 · Cited by 172
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L. T., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae029 · Cited by 156
Fleseriu, M., & Biller, B. M. K. (2022) · Pituitary · doi:10.1007/s11102-022-01268-2 · Cited by 54
Poplicean, E., Crișan, A. F., Tudorache, E., Hogea, P., Mladin, R., & Oancea, C. I. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226699 · Cited by 32
“Oral corticosteroids given for prolonged periods decrease patients’ immunity and have an increased risk of psychosis, hypertension, adrenocortical insufficiency, and osteopenia [45,137–139].”
Burden of Oral Corticosteroid Use in Severe Asthma: Challenges and Opportunities
Canonica, G. W., Porsbjerg, C. M., Price, D. B., Wechsler, M. E., Heaney, L. G., Hanania, N. A., Gall, R., Pandit‐Abid, N., Jacob-Nara, J. A., & Sacks, H. J. (2025) · Allergy · doi:10.1111/all.16569 · Cited by 20
Metadata
- Authors
- Pelewicz, K., & Miśkiewicz, P.
- Affiliations
- Medical University of Warsaw (PL)
- Corresponding author
- Miśkiewicz, Piotr
- Venue
- Diagnostics
- Publisher
- MDPI AG
- Published
- 2021-04-20
- Volume
- 11
- Issue
- 4
- Pages
- 728
- ISSN
- 2075-4418 (ISSN-L)
- PMC
- PMC8072923
- OpenAlex
- W3154233620
- Semantic Scholar
- d07efcd5a328cd3377c47a0a3a5a13f1cef48fb6
- Cited by
- 44
- References
- 72
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 11 · 2023: 15 · 2022: 2 · 2021: 3
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diagnostics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- glucocorticoid-induced adrenal insufficiency, glucocorticoid withdrawal, glucocorticoid tapering, adrenal suppression, hypothalamic-pituitary-adrenal axis, glucocorticoid replacement therapy, low-dose glucocorticoid therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.